Michael Deveau
Clinical Associate ProfessorResearch and Scholarly Interests
Radiation Oncology:
- Personalized radiotherapeutic prescriptions using functional imaging and 3D printing fabrication and implementation to address clinical and didactic deficiencies
- Functional Imaging
Biography
"My research involves clinical trials utilizing advanced imaging (CT, MRI, PET/CT) and radiotherapeutic modalities (helical tomotherapy) in tumor-induced research subjects and client owned companion animals with spontaneous tumors. These spontaneous tumors in patients share similarities with their human counterparts. From a translational perspective, spontaneous tumors in veterinary companion animals have been under-utilized for decades as a preclinical model for human cancer. However, such focus does not obviate the need for novel applications in rodent models as a transition from bench top ultimately towards clinics. My collaborative work with and advanced training in human medical physics in combination with my board certification in veterinary radiation oncology makes me uniquely qualified for this application. I have broad and specialized experience in the utilization of advanced radiotherapeutic strategies in the conditioning off or managing different tumor types in research models and companion animals."
Education
University of Wisconsin-Madison, School of Medicine and Public Health | Madison, WI
Master of Science in Medical Physics, 2010
Diplomate of the American College of Veterinary Radiology | Mechanicsburg, PA
Radiation Oncology, 2009
University of Wisconsin-Madison, School of Veterinary Medicine | Madison, WI
Radiation Oncology Residency, 2008
VCA Veterinary Referral and Emergency Center | Norwalk, CT
Small Animal Emergency Medicine and Surgery Internship, 2006
Kansas State University, College of Veterinary Medicine | Manhattan, KS
Doctor of Veterinary Medicine, 2005
University of Florida, College Of Agricultural And Life Sciences | Gainesville, FL
Bachelor of Science in Microbiology and Cell Science, 1996
Licensure
Texas Board of Veterinary Medical Examiners - 12209
Honors & Awards
| Award/Honor | Organization | Year |
|---|---|---|
| Katherine and Rebecca Rochelle Chair in Oncology | 2016 | |
| TL1 Training Program Award | Institute for Clinical and Translation Research | 2009-2010 |
Professional Organizations
- 2013 - Present, Veterinary Cancer Society, Member
- 2012 - Present, Society of Veterinary Nuclear Science
- 2006 - Present, American Veterinary Medical Association (AVMA), Member
- 2009 - 2010, American Association of Physicists in Medicine (AAPM), Student Member
- 2008 - 2009, Postdoctoral (Professional) Fellow, Dept. of Medical Physics, University of Wisconsin, Madison, WI
|
Conferring Organization |
Title |
Description |
|---|---|---|
|
Nanospectra Biosciences |
Pilot Study of Aurolase® Therapy for the Treatment of Solid Tumors in Canine and Feline Patients |
|
|
AKC Oak Grant 1585 |
Phase I Study of Involved-Field Radiotherapy for Advanced Stage Canine Lymphoma |
|
I provide core instruction in radiation oncology and therapeutic-oriented medical physics to interns, residents, faculty, graduate students and 4th year veterinary medicine students required to perform high quality multidisciplinary research and state-of-the-art clinical practice.
Graduate Students
- Mohammed Abusalem, 2017-present
- Ryan Clanton, 2015-2018
- Pankaj Patel, 2015-2018
- Gleb Kuzmin, 2014-2018
- Jordan Douglas, 2014-2018
- Michael Martin, 2016-2017
- Zaher Hamoui, 2014-2015
Residents/Interns/Postdoc Fellows
- Amanda Brehm, 2017-present
- Carrissa Wood, 2015-present
- Kendra Lyons, 2016-2017
- Jacqueline Bloch, 2014-2017
- Rita Ho, 2013-2014
- Megan Sutton, 2012-2015
- Jesse Grayton, 2011-2014
- Nicole Wilson, 2011-2012
My prior contributions to science examined, as a model for cancer treatment in humans, the utilization of PET-based imaging biomarkers to characterize tumor biological phenotypes while guiding clinical implementation of biomarker-driven radiotherapeutic strategies to improve clinical outcomes in veterinary canine companion animals with sinonasal tumors. Radiation therapy is an integral part of modern cancer treatment in humans with a number of studies demonstrating most local failures in head and neck and prostate cancers typically occurring in regions that received the highest dose. Due to the biological complexity of tumor resistance, treatment outcome remains difficult to predict. These publications explored a number of different PET-based biomarkers as surrogates of resistance to radiation therapy and/or investigated the feasibility (clinical implementability) of continuous dose painting strategies using a commercial treatment planning system products. Dose painting is an alternate radiation delivery strategy which incorporates functional information into the radiation dose prescription in an attempt to remove dose from radiosensitive regions of the target in order to increase it to radioresistant parts while preserving the same energy imparted to the patient.
- Bradshaw TJ, Bowen SR, Deveau MA, Kubicek L, White P, Bentzen SM, Chappell RJ, Forrest LJ, Jeraj R.Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):787-95. doi: 10.1016/j.ijrobp.2014.12.011. PubMed PMID: 25752393; PubMed Central PMCID: PMC4355478.
- Bowen SR, Chappell RJ, Bentzen SM, Deveau MA, Forrest LJ, Jeraj R. Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. Radiother Oncol. 2012 Oct;105(1):41-8. doi: 10.1016/j.radonc.2012.05.002. Epub 2012 Jun 8. PubMed PMID: 22682748; PubMed Central PMCID: PMC3489967.
- Korreman SS, Ulrich S, Bowen S, Deveau M, Bentzen SM, Jeraj R. Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta Oncol. 2010 Oct;49(7):964-71. doi: 10.3109/0284186X.2010.498440. PubMed PMID: 20831483; PubMed Central PMCID: PMC3055798.
- Deveau MA, Bowen SR, Westerly DC, Jeraj R. Feasibility and sensitivity study of helical tomotherapy for dose painting plans. Acta Oncol. 2010 Oct;49(7):991-6. doi: 10.3109/0284186X.2010.500302. PubMed PMID: 20831487; PubMed Central PMCID: PMC3040036.